NxGEN Vector Solutions is pleased to share its new company profile in Life Sciences Review, “Solving Gene Therapy’s Immune Puzzle.”

The feature recognizes NxGEN as the exclusive recipient of the publication’s Top Gene Therapy Solution 2025 distinction and highlights our patented CpG-depletion platform for improving the safety, durability, and clinical reliability of AAV-based gene therapies.

The article explores how NxGEN’s genome-optimization approach addresses immune activation at its source, supports sustained therapeutic gene expression, and helps developers reduce risk when designing next-generation gene therapies.

Read the full NxGEN Vector Solutions profile.